SCHEMBL29610030

SCHEMBL29610030

NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 5/20 0.59
DPP7 Q9UHL4 5/20 0.59
DPP8 Q6V1X1 4/20 0.59
DPP9 Q86TI2 3/20 0.59
FAP Q12884 2/20 0.59
ACE P12821 6/20 0.54
REN P00797 3/20 0.54
KDM4E B2RXH2 1/20 0.51
F2 P00734 1/20 0.51
LMNA P02545 1/20 0.51
LTA4H P09960 1/20 0.51
MAPT P10636 1/20 0.51
PEPD P12955 1/20 0.51
ALOX15 P16050 1/20 0.51
PTGS1 P23219 1/20 0.51
HTR2A P28223 1/20 0.51
PTGS2 P35354 1/20 0.51
HRH1 P35367 1/20 0.51
THPO P40225 1/20 0.51
PMP22 Q01453 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2113947 1.00 DPP4 (0.59) DPP4DPP7DPP8DPP9FAP
SCHEMBL2113944 1.00 DPP4 (0.59) DPP4DPP7DPP8DPP9FAP
SCHEMBL27796855 0.96 DPP7 (0.65) DPP4DPP7DPP8DPP9FAP
SCHEMBL29374265 0.96 DPP7 (0.65) DPP4DPP7DPP8DPP9FAP
SCHEMBL2113409 0.96 DPP7 (0.65) DPP4DPP7DPP8DPP9FAP
SCHEMBL2113410 0.96 DPP7 (0.65) DPP4DPP7DPP8DPP9FAP
SCHEMBL2123080 0.96 DPP7 (0.65) DPP4DPP7DPP8DPP9FAP
SCHEMBL2123083 0.96 DPP7 (0.65) DPP4DPP7DPP8DPP9FAP
SCHEMBL31735178 0.91 DPP7 (0.62) DPP4DPP7DPP8DPP9FAP
SCHEMBL10829152 0.91 DPP7 (0.60) DPP4DPP7DPP8DPP9FAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025245279-A1 NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR AGONISTS AND USE THEREFORE IN TREATMENT OF ADDICTION AND/OR PAIN ENDEVICA BIO, INC. (US) 2025-11-27 WO claimed
WO-2025245252-A1 NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR AGONIST ANALOGS FOR USE IN PAIN MANAGEMENT AND/OR SUBSTANCE USE DISORDERS ENDEVICA BIO, INC. (US) 2025-11-27 WO claimed
WO-2025245244-A1 NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR AGONIST ANALOGS FOR MODULATING WEIGHT LOSS ENDEVICA BIO, INC. (US) 2025-11-27 WO claimed
WO-2025245294-A1 NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR AGONISTS AND USES THEREOF FOR MODULATING WEIGHT GAIN ENDEVICA BIO, INC. (US) 2025-11-27 WO claimed
WO-2025245292-A1 NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR AGONISTS AND USES THEREOF FOR MODULATING WEIGHT LOSS ENDEVICA BIO, INC. (US) 2025-11-27 WO claimed
WO-2025245258-A1 NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR AGONIST ANALOGS FOR MODULATING WEIGHT GAIN ENDEVICA BIO, INC. (US) 2025-11-27 WO claimed
WO-2025245258-A1 NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR AGONIST ANALOGS FOR MODULATING WEIGHT GAIN ENDEVICA BIO, INC. (US) 2025-11-27 WO disclosed
WO-2025245252-A1 NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR AGONIST ANALOGS FOR USE IN PAIN MANAGEMENT AND/OR SUBSTANCE USE DISORDERS ENDEVICA BIO, INC. (US) 2025-11-27 WO disclosed
WO-2025245294-A1 NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR AGONISTS AND USES THEREOF FOR MODULATING WEIGHT GAIN ENDEVICA BIO, INC. (US) 2025-11-27 WO disclosed
WO-2025245292-A1 NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR AGONISTS AND USES THEREOF FOR MODULATING WEIGHT LOSS ENDEVICA BIO, INC. (US) 2025-11-27 WO disclosed
WO-2025245279-A1 NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR AGONISTS AND USE THEREFORE IN TREATMENT OF ADDICTION AND/OR PAIN ENDEVICA BIO, INC. (US) 2025-11-27 WO disclosed
WO-2025245244-A1 NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR AGONIST ANALOGS FOR MODULATING WEIGHT LOSS ENDEVICA BIO, INC. (US) 2025-11-27 WO disclosed
US-11945848-B2 Chimeric inhibitor molecules of complement activation OMEROS CORPORATION (US) 2024-04-02 US disclosed
US-20230295252-A1 CHIMERIC INHIBITOR MOLECULES OF COMPLEMENT ACTIVATION OMEROS CORPORATION (US) 2023-09-21 US disclosed
US-20230159629-A1 COMPOSITIONS AND METHOD OF MODULATING GROWTH FACTOR FUNCTION NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-05-25 US disclosed
US-20230151084-A1 COMPOSITIONS AND METHODS OF MODULATING B CELL RESPONSE UNIV CASE WESTERN RESERVE (US) 2023-05-18 US disclosed
US-11453709-B2 Chimeric inhibitor molecules of complement activation OMEROS CORPORATION (US) 2022-09-27 US disclosed
US-20220185872-A1 METHOD FOR INHIBITING PLATELET DERIVED GROWTH FACTOR SIGNALING WITH C3aR OR C5aR ANTIBODIES NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-06-16 US disclosed